New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
08:45 EDTANIKAnika Therapeutics price target raised to $60 from $47 at Summer Street
Summer Street raised its price target for Anika Therapeutics shares to $60 after the FDA approved Monovisc. The firm reiterates a Buy rating on the stock.
News For ANIK From The Last 14 Days
Check below for free stories on ANIK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
13:48 EDTANIKAnika Therapeutics weakness creates buying opportunity, at Summer Street
Subscribe for More Information
11:58 EDTANIKAnika Therapeutics management to meet with JMP Securities
Subscribe for More Information
July 30, 2014
16:31 EDTANIKAnika Therapeutics reports Q2 EPS 60c, consensus 57c
Subscribe for More Information
13:05 EDTANIKAnika Therapeutics announces U.S. commercialization partnership with Medline
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use